What's Happening?
A new study published in the Annals of Internal Medicine suggests that GLP-1 drugs, such as Ozempic and Zepbound, likely have little or no effect on the risk of developing 13 obesity-related cancers. The research analyzed data from 48 randomized controlled
trials involving over 94,000 patients with Type 2 diabetes, overweight, or obesity. The study found that GLP-1 drugs did not significantly alter the risk of cancers such as breast, kidney, thyroid, and pancreatic, among others.
Why It's Important?
The findings provide reassurance regarding the safety of GLP-1 drugs, which are widely used for weight loss and diabetes management. While previous studies suggested a potential cancer risk reduction, this comprehensive analysis indicates that GLP-1 drugs do not increase cancer risk, supporting their continued use in managing obesity and diabetes. However, the study also highlights the need for longer-term research to fully understand the long-term effects of these medications on cancer risk.
